ClinicalTrials.gg
Active, not recruitingNCT05219500TATCISTUpdated Apr 3, 2026

Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).

A Phase 2 interventional study of FPI-2265 in Metastatic Castration Resistant Prostate Cancer, sponsored by Fusion Pharmaceuticals Inc.. Active, not recruiting at 2 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Fusion Pharmaceuticals Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
115
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in Prostatic Neoplasms by AstraZeneca — 15 open to participants now, 29 under way, 8 of them phase 3. Prostatic Neoplasms · AstraZeneca.

Planned enrollment
28th of 60
115 · median 110
Started
2021
with 7 others
Phase 2
16 of 91
none open now
Primary completion
2025-05
later than 4 of 28 live
Registered
63rd of 91
by date

Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 28th largest by planned enrollment of the 60 interventional ones that give a count, is one of 8 that started in 2021, is one of 16 in phase 2, reaches primary completion later than 4 of the 28 other live ones, and was the 63rd registered.

Prostatic Neoplasms

7,047 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 91 studies in Prostatic Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Prostatic Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

The treatment regimen will consist of 4 doses of FPI-2265

Read the detailed description

The treatment regimen will consist of 4 doses of FPI-2265, administered at 8 ± 1 week intervals, with an initial activity of 100 kilobecquerel (kBq)/kg (±10%).

Additional doses will be administered at 100 kBq/kg (±10%) with the following exceptions:

  • Participants who experience dose-modifying events.
  • Participants with a confirmed decline in PSA>=50%.
03

Conditions studied

  • Metastatic Castration Resistant Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants aged ≥ 18 years.
  2. Participants must have the ability to understand and sign an approved (ICF).
  3. Participants must have the ability to understand and comply with all protocol requirements.
  4. Adenocarcinoma of prostate proven by histopathology.
  5. of 6 months or more.
  6. Unresectable .
  7. Documented progressive disease (PD); progressive mCRPC will be based on at least 1 of the following criteria:

    1. Serum PSA progression is defined as 2 consecutive increases in PSA over a previous reference value measured at least 1 week prior. The minimal starting value is 1.0 ng/mL, if PSA is the only indication of progression.
    2. Soft-tissue progression defined as an increase ≥ 20% in the sum of the diameter (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest SOD since treatment started or the appearance of one or more new lesions.
    3. Progression of bone disease: evaluable disease or new bone lesions(s) by bone scan (2+2 PCWG3 criteria).
  8. If known Breast Cancer gene (BRCA) mutations are present, participants should have received FDA approved therapies such as poly-ADP ribose polymerase (PARP) inhibitors and progressed.
  9. Castration resistant disease with confirmed testosterone level ≤ 50 ng/dL under prior androgen deprivation therapy (ADT). Must have a castrate level of serum testosterone (\< 50 ng/dL or \< 1.7 nmol/L).
  10. Positive PSMA PET/CT scans, obtained with approved PSMA-ligands, defined as at least one PSMA-positive metastatic lesion and no PSMA-negative lesions.
  11. -PS 0 to 1.
  12. (Hgb) concentration ≥ 9.0 g/dL.
  13. counts ≥ 100 × 10\^9/L.
  14. White blood cell (WBC) count ≥ 2.0 × 10\^9/L, (ANC) > 1.5 × 10\^9/L.

    a. Hematological criteria cannot be met with ongoing or recent blood transfusions (within 7 days prior to the scheduled first dose of study treatment) or require growth factor support (within 21 days prior to the scheduled first dose of study treatment).

  15. or aspartate aminotransferase ≤ 3.0 × (ULN).
  16. Serum total ≤ 1.5 × ULN; in participants with Gilbert's syndrome, a total bilirubin ≤ 3 times ULN and direct bilirubin within normal limits are permitted.
  17. Albumin ≥ 2.5 g/dL.
  18. Serum/plasma creatinine ≤ 1.5 × ULN or ≥ 60 mL/min based on the Cockcroft-Gault formula.
  19. , international normalized ratio or prothrombin time test \< 1.5 × ULN.
  20. Received ≥ 1 androgen receptor axis-targeted therapies (ARAT).
  21. Participants on anti-androgen therapy are allowed to continue their treatment at the discretion of their treating physician.

Exclusion criteria

Exclusion Criteria:

  1. Less than 6 weeks from enrollment since last myelosuppressive therapy (including Docetaxel, Cabazitaxel, 223Ra, 153Sm, 177Lu-PSMA-617/other Lu-PSMA RLT or any other radionuclide therapy). Participants who received previous treatment with Ac-225 are excluded.
  2. Participants who received more than 4 for CRPC.
  3. Urinary tract obstruction as evidenced by Tc-99m DTPA renal scan with diuretics.
  4. Participants with skeletal presenting as a superscan on a 99m Tc MDP Bone Scan.

    Superscan is defined as a bone scan which demonstrates markedly increased skeletal radioisotope uptake relative to soft tissues in association with absent or faint renal activity (absent kidney sign).

  5. Persistent baseline dry eye or dry mouth > Grade 1 from prior RLT.
  6. Persistent prior AEs > Grade 1 from prior anti-cancer therapies.
  7. Abnormal renal function (estimated \< 60 mL/min), baseline \< 9g/dL, ANC \< 1.5 ×10\^9/L, \< 100 ×10\^9/L, and , international normalized ratio or prothrombin time test ≥ 1.5 × .
  8. Administration of an agent ≤ 60 days or 5 half-lives, whichever is shorter, prior to Cycle 1, Week 0.
  9. Known presence of central nervous system (CNS) metastases or liver metastases.
  10. Active other than low-grade non-muscle-invasive bladder cancer and non-melanoma skin cancer.
  11. Concurrent illness that may jeopardize the participant's ability to undergo study procedures as determined by the Investigator.
  12. Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression.
  13. Concurrent serious (as determined by the investigator) medical conditions, including, but not limited to, Class III or IV congestive heart failure, unstable ischemia, uncontrolled symptomatic arrhythmia, history of congenital prolonged syndrome, uncontrolled infection, known active or C, or other significant co-morbid conditions that in the opinion of the Investigator would impair study participation or cooperation.
  14. Major surgery ≤ 30 days prior to enrollment.
  15. Planning to conceive pregnancy during the treatment and up to 6 months after the last treatment.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
115 participants (estimated)

Study arms

  • Experimental
    FPI-2265

    All patients will receive FPI-2265, administered at 8 ± 1-week interval, with the initial activity of 100 kBq/kg (±10%).

    Drug: FPI-2265

Interventions

  • Small molecule capable of binding to the domain of PSMA radiolabeled with Ac225

    Also known as: Ac225-PSMA I&T

06

What researchers measure

Primary outcomes

  1. To evaluate the effect of FPI-2265 on prostate-specific antigen (PSA) in participants with mCRPC.

    Frequency and proportion of participants with PSA50, defined as ≥ 50% decline in PSA level by 12-weeks after the first treatment.

    Time frame: From start of treatment until 12 weeks after the first treatment.

Secondary outcomes

  1. To evaluate the safety and tolerability of FPI- 2265.

    * Frequency, duration and severity of treatment emergent adverse events (TEAEs) evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0). * Changes in clinical laboratory, electrocardiograms (ECGs) and physical examinations compared to baseline.

    Time frame: From first treatment dose to up to 24 months after last treatment.

  2. To evaluate the anti-tumor activity of FPI-2265.

    * Maximum % PSA decline. * PSA progression free survival (PFS). * Time to best PSA response * Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). * Disease control rate (DCR) per RECIST v1.1. * Duration of response (DoR) based on RECIST v1.1/Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria. * Radiographic progression-free survival (rPFS) per PCWG3 criteria. * Overall survival (OS).

    Time frame: From first treatment until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 24 months after last treatment.

  3. To assess the impact of FPI-2265 on participant reported outcomes.

    * The frequency and proportion of participants with an improvement in bone pain levels. * Change in quality of life (QoL) over time.

    Time frame: From first treatment until 24 months after last treatment.

07

Study locations

2 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in May 2025, 41 months.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 41 months is above that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2021
First posted
Feb 2, 2022
StartActual
Dec 16, 2021
Primary completionActual
May 30, 2025
CompletionEst.
Jul 31, 2026
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05219500
Responsible party
Sponsor
First posted
Feb 2, 2022
Start date
Dec 16, 2021
Primary completion
May 30, 2025
Completion
Jul 31, 2026 (estimated)
Last update
Apr 3, 2026

Study contacts

Keith Barnett
study director · Fusion Pharmaceuticals Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Actinium zadavotide guraxetan AC-225

Start the discussion